Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
Primary Purpose
Cervical Cancer
Status
Completed
Phase
Phase 4
Locations
Tanzania
Study Type
Interventional
Intervention
Gardasil® HPV vaccine
Sponsored by
About this trial
This is an interventional prevention trial for Cervical Cancer focused on measuring human papillomavirus, vaccine, school girls, Tanzania, acceptability, vaccine coverage, Cervical cancer prevention
Eligibility Criteria
Inclusion Criteria:
- female pupil
- attends selected school
- born in 1998 if enrolled in school selected for age-based delivery
- attending standard (class) 6 if enrolled in school selected for class-based delivery
Exclusion Criteria:
- has not previously received HPV vaccine
- has not participated in previous HPV vaccine trials
Sites / Locations
- National Institute for Medical Research
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Class-based delivery
Age-based delivery
Arm Description
All girls attending standard 6 in schools selected for class-based vaccine delivery
All girls born in 1998 attending schools selected for age-based delivery
Outcomes
Primary Outcome Measures
Vaccine coverage by delivery strategy
Vaccine coverage will be estimated for each dose given and for those completing the full course of vaccination and compared by delivery strategy.
Vaccine coverage (dose 2) by delivery strategy
Vaccine coverage (dose 1) by delivery strategy
Secondary Outcome Measures
Factors associated with refusal to vaccinate or to complete vaccination course
A case control study to determine factors associated with refusal will be conducted on a 1:1 sample of 350 vaccine refusers and 350 accepters.
Identification of barriers to HPV vaccination
Qualitative research will be conducted to examine barriers to vaccination and reasons for failure to complete vaccination.
Estimation of the costs of introducing and scaling up HPV vaccines in schools
Full financial and economic costs from the provider's perspective will be collected for the intervention. Total costs of a district vaccination programme and cost per urban school and rural school reached (if urban/rural differences are identified) and cost per fully-vaccinated girl will be estimated for the two alternative delivery strategies.
Full Information
NCT ID
NCT01173900
First Posted
July 28, 2010
Last Updated
November 5, 2011
Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
National Institute for Medical Research, Tanzania, Ocean Road Cancer Institute, Tanzania, Institut Català d' Oncologia, Spain, Medical Research Council Social & Public Health Sciences Unit, UK, International Union Against Cancer, Switzerland
1. Study Identification
Unique Protocol Identification Number
NCT01173900
Brief Title
Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
Official Title
Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
Study Type
Interventional
2. Study Status
Record Verification Date
November 2011
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
National Institute for Medical Research, Tanzania, Ocean Road Cancer Institute, Tanzania, Institut Català d' Oncologia, Spain, Medical Research Council Social & Public Health Sciences Unit, UK, International Union Against Cancer, Switzerland
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aims of this study are:
To determine feasibility of a school-based human papillomavirus (HPV) vaccination programme in Tanzania.
To measure the uptake and acceptability of two different vaccination strategies in rural and urban schools.
To examine the characteristics of accepters/refusers of vaccination and to identify reasons for acceptance, refusal or non-completion.
To measure the cost of implementing a school-based HPV vaccination programme in Tanzania.
Detailed Description
Vaccines against human papillomavirus infection, the primary cause of cervical cancer, are an attractive cervical cancer prevention strategy for resource poor settings which lack the infrastructure for establishing and maintaining complex screening programmes.Feasibility and costs of setting up and sustaining an HPV vaccination programme will depend on whether it can be added onto an existing health programme within schools, if one exists, or whether it has to be established as a separate health intervention. Other factors will also affect vaccine coverage. For example, uptake and overall effectiveness will be critically dependent on parental and community acceptability of a vaccine that prevents a sexually transmitted infection and how the vaccine is promoted and delivered by health-care providers will influence its uptake and acceptability.
This study will determine feasibility, uptake and acceptability of different delivery strategies of school-based HPV vaccination in Tanzania, examine factors related to acceptance or refusal of vaccination and measure the cost of implementing a school-based HPV vaccination programme in Tanzania.
Three doses of quadrivalent human papillomavirus (HPV) vaccine, (Gardasil®; Merck & Co) given at 0, 2 and 6 months, will be provided to 5000 primary school girls at 134 randomly selected schools in Mwanza Region in Tanzania. Selected schools will be randomly assigned to one of two delivery strategies (age-based or class-based) and coverage and acceptability of these vaccine delivery strategies will be compared. Qualitative research will be conducted before, during and after vaccination to examine barriers to vaccination and reasons for failure to complete vaccination as well as general community perceptions. To determine factors associated with refusal a case control study will be conducted on a 1:1 sample of 350 vaccine refusers and 350 accepters. The costs of introducing and scaling up HPV vaccines in schools will be estimated using established costing methods.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Cancer
Keywords
human papillomavirus, vaccine, school girls, Tanzania, acceptability, vaccine coverage, Cervical cancer prevention
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5532 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Class-based delivery
Arm Type
Other
Arm Description
All girls attending standard 6 in schools selected for class-based vaccine delivery
Arm Title
Age-based delivery
Arm Type
Other
Arm Description
All girls born in 1998 attending schools selected for age-based delivery
Intervention Type
Biological
Intervention Name(s)
Gardasil® HPV vaccine
Intervention Description
0.5 ml given at 0, 2, 6 months
Primary Outcome Measure Information:
Title
Vaccine coverage by delivery strategy
Description
Vaccine coverage will be estimated for each dose given and for those completing the full course of vaccination and compared by delivery strategy.
Time Frame
Month 12
Title
Vaccine coverage (dose 2) by delivery strategy
Time Frame
Month 5
Title
Vaccine coverage (dose 1) by delivery strategy
Time Frame
Month 3
Secondary Outcome Measure Information:
Title
Factors associated with refusal to vaccinate or to complete vaccination course
Description
A case control study to determine factors associated with refusal will be conducted on a 1:1 sample of 350 vaccine refusers and 350 accepters.
Time Frame
Month 12
Title
Identification of barriers to HPV vaccination
Description
Qualitative research will be conducted to examine barriers to vaccination and reasons for failure to complete vaccination.
Time Frame
Month 14
Title
Estimation of the costs of introducing and scaling up HPV vaccines in schools
Description
Full financial and economic costs from the provider's perspective will be collected for the intervention. Total costs of a district vaccination programme and cost per urban school and rural school reached (if urban/rural differences are identified) and cost per fully-vaccinated girl will be estimated for the two alternative delivery strategies.
Time Frame
Month 10
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
9 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
female pupil
attends selected school
born in 1998 if enrolled in school selected for age-based delivery
attending standard (class) 6 if enrolled in school selected for class-based delivery
Exclusion Criteria:
has not previously received HPV vaccine
has not participated in previous HPV vaccine trials
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deborah :L Watson-Jones, MD, PhD
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Richard J Hayes, DSC
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
John Changalucha, BSc
Organizational Affiliation
National Institute for Medical Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institute for Medical Research
City
Mwanza
Country
Tanzania
12. IPD Sharing Statement
Citations:
PubMed Identifier
23148516
Citation
Quentin W, Terris-Prestholt F, Changalucha J, Soteli S, Edmunds WJ, Hutubessy R, Ross DA, Kapiga S, Hayes R, Watson-Jones D. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Med. 2012 Nov 13;10:137. doi: 10.1186/1741-7015-10-137.
Results Reference
derived
PubMed Identifier
22711908
Citation
Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjose S, Wight D, Changalucha J, Hayes R. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis. 2012 Sep 1;206(5):678-86. doi: 10.1093/infdis/jis407. Epub 2012 Jun 18.
Results Reference
derived
Learn more about this trial
Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
We'll reach out to this number within 24 hrs